Compare Hyatt Hotels Corporation (H) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Hyatt Hotels Corporation trades at $160.01 (market cap $15.11B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M). The key difference: Hyatt Hotels Corporation is far larger — about 15.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Hyatt Hotels Corporation pays a 0.37% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 149 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| H | MRVI | |
|---|---|---|
Market Cap | $15.11B | $977.37M |
Volume | 769,803 | 2,742,564 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $9.00 |
52-Week Low | $135.42 | $2.83 |
Typical Hold Time | 149 Days | 0 Days |
Enterprise Value | $19.01B | $1.08B |
Dividend Yield | 0.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $162.92, up 1.08% on the day, with a bullish technical signal and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026. The stock is supported by a consensus price target of $197.92, representing a 21% upside, and positive news including a strategic loyalty collaboration with Delta Air Lines and portfolio expansion. However, valuation metrics like a P/E of 197.93 and a net income margin of 1.1% indicate premium pricing relative to modest profitability.
The outlook for H is cautiously optimistic, driven by earnings momentum and strategic initiatives, but high valuation and fluctuating cash flows pose risks. Investors should weigh the potential for continued operational growth against the stock's rich multiples and macroeconomic sensitivity in the hospitality sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
